New imaging technique could improve prostate cancer treatment monitoring

NCT ID NCT07221825

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times

Summary

This study aims to see if a special type of scan (low-count quantitative SPECT) can accurately measure where the drug Radium-223 goes in the body. Radium-223 is a radioactive treatment for prostate cancer that has spread to bones, but doctors don't know exactly how much reaches the tumors or healthy organs. About 38 men who are already eligible for Radium-223 will get extra scans to check if this imaging method works well and is safe. The goal is to improve future treatment planning and drug development.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.